Vetoquinol - Asset Resilience Ratio

Latest as of June 2025: 1.45%

Vetoquinol (VETO) has an Asset Resilience Ratio of 1.45% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€10.53 Million
≈ $12.31 Million USD Cash + Short-term Investments

Total Assets

€725.82 Million
≈ $848.56 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2005–2024)

This chart shows how Vetoquinol's Asset Resilience Ratio has changed over time. Check Vetoquinol PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Vetoquinol's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see VETO stock market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €10.53 Million 1.45%
Total Liquid Assets €10.53 Million 1.45%

Asset Resilience Insights

  • Limited Liquidity: Vetoquinol maintains only 1.45% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Vetoquinol Industry Peers by Asset Resilience Ratio

Compare Vetoquinol's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Takeda Pharmaceutical Company Limited
F:TKDA
Drug Manufacturers - Specialty & Generic 0.69%
Sandoz Group AG
SW:SDZ
Drug Manufacturers - Specialty & Generic 7.89%
Viatris Inc
NASDAQ:VTRS
Drug Manufacturers - Specialty & Generic 1.62%
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
Drug Manufacturers - Specialty & Generic 5.22%
Humanwell Healthcare Group Co Ltd
SHG:600079
Drug Manufacturers - Specialty & Generic 2.75%
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
Drug Manufacturers - Specialty & Generic 4.31%
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
Drug Manufacturers - Specialty & Generic 43.05%
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Drug Manufacturers - Specialty & Generic 5.90%

Annual Asset Resilience Ratio for Vetoquinol (2005–2024)

The table below shows the annual Asset Resilience Ratio data for Vetoquinol.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 2.80% €20.82 Million
≈ $24.34 Million
€744.13 Million
≈ $869.97 Million
+2.99pp
2023-12-31 -0.19% €-1.32 Million
≈ $-1.55 Million
€692.23 Million
≈ $809.29 Million
-4.53pp
2022-12-31 4.34% €28.28 Million
≈ $33.06 Million
€651.85 Million
≈ $762.08 Million
+1.88pp
2021-12-31 2.46% €15.34 Million
≈ $17.93 Million
€624.56 Million
≈ $730.18 Million
+2.46pp
2020-12-31 0.00% €1.00K
≈ $1.17K
€646.09 Million
≈ $755.35 Million
-3.62pp
2019-12-31 3.62% €18.51 Million
≈ $21.64 Million
€511.47 Million
≈ $597.96 Million
-9.09pp
2018-12-31 12.71% €59.17 Million
≈ $69.18 Million
€465.58 Million
≈ $544.32 Million
+3.94pp
2017-12-31 8.77% €38.95 Million
≈ $45.53 Million
€443.97 Million
≈ $519.05 Million
+0.64pp
2016-12-31 8.13% €35.71 Million
≈ $41.75 Million
€439.17 Million
≈ $513.44 Million
+8.21pp
2012-12-31 -0.07% €-261.00K
≈ $-305.14K
€356.44 Million
≈ $416.71 Million
-0.07pp
2006-12-31 0.00% €-3.00K
≈ $-3.51K
€210.62 Million
≈ $246.24 Million
+0.00pp
2005-12-31 0.00% €-4.00K
≈ $-4.68K
€199.72 Million
≈ $233.49 Million
--
pp = percentage points

About Vetoquinol

PA:VETO France Drug Manufacturers - Specialty & Generic
Market Cap
$987.70 Million
€844.84 Million EUR
Market Cap Rank
#9076 Global
#146 in France
Share Price
€71.60
Change (1 day)
+1.13%
52-Week Range
€67.20 - €91.00
All Time High
€149.34
About

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal … Read more